A cytidine deaminase inhibitor
Technical Support & Resources

Information provided in the product description is from published literature. Due to the nature of scientific experimentation, your results (e.g., selectivity and effective concentrations) or specific application for this product may differ. If you have questions about how this product fits your application, please contact our technical support staff.

Visit our FAQ

Contact Us

Toll Free Phone (USA and Canada Only): (888) 526-5351
Direct Phone: (734) 975-3888

Request Technical Support

Technical Support Request

To streamline the process attach the appropriate questionnaire to your inquiry.

Download IHC QuestionnaireDownload WB Questionnaire

View Our Privacy Statement for details on how we use and protect your data. In addition, this site is protected by hCaptcha and its Privacy Policy and Terms of Service apply.

Cedazuridine

Item No. 38767

Technical Information
Formal Name
(4R)-2′-deoxy-2′,2′-difluoro-3,4,5,6-tetrahydro-uridine
CAS Number
1141397-80-9
Synonyms
  • E7727
Molecular Formula
C9H14F2N2O5
Formula Weight
Purity
≥95%
A crystalline solid
SMILES
FC1([C@H](N2C(N[C@@H](CC2)O)=O)O[C@@H]([C@H]1O)CO)F
InChi Code
InChI=1S/C9H14F2N2O5/c10-9(11)6(16)4(3-14)18-7(9)13-2-1-5(15)12-8(13)17/h4-7,14-16H,1-3H2,(H,12,17)/t4-,5-,6-,7-/m1/s1
InChi Key
VUDZSIYXZUYWSC-DBRKOABJSA-N
Shipping & Storage Information
Storage
-20°C
Shipping
Room temperature in continental US; may vary elsewhere
Recommended Products

Certificates of Analysis & Batch Specific Data

Provide batch numbers separated by commas to download or request available product inserts, QC sheets, certificates of analysis, data packs, and GC-MS data.

    Add

    Add

    Add

    Add

    Cayman Chemical
    Visit Our Cancer Resource Center
    Find Tools & Resources to Study the Hallmarks of Cancer
    • Cancer cell signaling & regulation
    • Cancer metabolism
    • Tumor microenvironment
    EXPLORE NOW
    Product Description

    Cedazuridine is an inhibitor of cytidine deaminase (IC50 = 0.4 µM).1 It increases plasma levels of decitabine via inhibition of its metabolism by cytidine deaminase in rhesus monkeys when administered at doses of 1 and 10 mg/kg. Cedazuridine (3 mg/kg) induces decreases in leukemic cell expansion in combination with orally administered 5-azacytidine (Item No. 11164), which is inactive as a single agent, in the bone marrow and spleen in a MOLM-13 acute myeloid leukemia (AML) mouse xenograft model.2 Formulations containing cedazuridine in combination with decitabine have been used in the treatment of myelodysplastic syndrome (MDS).

    WARNING This product is not for human or veterinary use.

    References & Product Citations
    Product Description References

    1. Ferraris, D., Duvall, B., Delahanty, G., et alDesign, synthesis, and pharmacological evaluation of fluorinated tetrahydrouridine derivatives as inhibitors of cytidine deaminase. J. Med. Chem. 57(6), 2582-2588 (2014).

    2. Ramsey, H.E., Oganesian, A., Gorska, A.E., et alOral azacitidine and cedazuridine approximate parenteral azacitidine efficacy in murine model. Target Oncol. 15(2), 231-240 (2020).